ECSP10010104A - Sistema de administración vaginal - Google Patents

Sistema de administración vaginal

Info

Publication number
ECSP10010104A
ECSP10010104A EC2010010104A ECSP10010104A ECSP10010104A EC SP10010104 A ECSP10010104 A EC SP10010104A EC 2010010104 A EC2010010104 A EC 2010010104A EC SP10010104 A ECSP10010104 A EC SP10010104A EC SP10010104 A ECSP10010104 A EC SP10010104A
Authority
EC
Ecuador
Prior art keywords
drospirenone
membrane
estrogen
core
compartment
Prior art date
Application number
EC2010010104A
Other languages
English (en)
Inventor
Vladimir Hanes
Christine Talling
Antti Keinaeenen
Svante Holmberg
Hannu Nikander
Original Assignee
Bayer Schering Pharma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40394262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010104(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07397043A external-priority patent/EP2062569B1/en
Priority claimed from EP07397042A external-priority patent/EP2062568A1/en
Application filed by Bayer Schering Pharma Oy filed Critical Bayer Schering Pharma Oy
Publication of ECSP10010104A publication Critical patent/ECSP10010104A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un sistema de administración intravaginal para la liberación controlada de drospirenona y un estrógeno y, opcionalmente, también comprende una o más sustancias terapéuticamente activas o promotoras de la salud capaces de brindar y/o mejorar la protección contra infecciones bacterianas y fúngicas, y/o mejorar la protección contra enfermedades de transmisión sexual. El sistema de administración comprende uno o más compartimientos, cada uno de los cuales comprende un núcleo y una membrana que recubre el núcleo, dicho núcleo y dicha membrana están compuestos esencialmente por la misma composición de polímero o una composición de polímero diferente, donde al menos un compartimiento comprende drospirenona y al menos un compartimiento, que puede ser igual o diferente del que comprende drospirenona, comprende un estrógeno o una mezcla de drospirenona y un estrógeno, y donde la membrana o la superficie de la membrana o al menos uno de los núcleos comprende dicha sustancia terapéuticamente activa o promotora de la salud.
EC2010010104A 2007-11-22 2010-04-14 Sistema de administración vaginal ECSP10010104A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07397043A EP2062569B1 (en) 2007-11-22 2007-11-22 Vaginal delivery system
EP07397042A EP2062568A1 (en) 2007-11-22 2007-11-22 Vaginal delivery system

Publications (1)

Publication Number Publication Date
ECSP10010104A true ECSP10010104A (es) 2010-06-29

Family

ID=40394262

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010104A ECSP10010104A (es) 2007-11-22 2010-04-14 Sistema de administración vaginal

Country Status (26)

Country Link
US (2) US20100285097A1 (es)
EP (1) EP2227220A1 (es)
JP (1) JP2011504484A (es)
KR (1) KR20100090708A (es)
CN (1) CN101873850A (es)
AR (1) AR069379A1 (es)
AU (1) AU2008327813A1 (es)
BR (1) BRPI0815936A2 (es)
CA (1) CA2705734A1 (es)
CL (1) CL2008003421A1 (es)
CO (1) CO6290642A2 (es)
CR (1) CR11493A (es)
DO (1) DOP2010000154A (es)
EA (1) EA018112B1 (es)
EC (1) ECSP10010104A (es)
IL (1) IL205588A0 (es)
MX (1) MX2010003656A (es)
NZ (1) NZ584216A (es)
PA (1) PA8805001A1 (es)
PE (1) PE20091025A1 (es)
SG (1) SG186002A1 (es)
SV (1) SV2010003513A (es)
TW (1) TW200927141A (es)
UY (1) UY31475A1 (es)
WO (1) WO2009066006A1 (es)
ZA (1) ZA201002122B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI121000B (fi) * 2008-11-19 2010-06-15 Bayer Schering Pharma Oy Intravaginaalinen antojärjestelmä ja menetelmä sen valmistamiseksi
US8822610B2 (en) * 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
WO2010123574A1 (en) 2009-04-23 2010-10-28 Atrp Solutions Inc Star macromolecules for personal and home care
WO2014036498A2 (en) 2012-08-30 2014-03-06 ATRP Solutions, Inc. Dual mechanism thickening agents for hydraulic fracturing fluids
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
FI20095550A0 (fi) * 2009-05-19 2009-05-19 Bayer Schering Pharma Oy Vaginaalinen antojärjestelmä
FI20095563A7 (fi) * 2009-05-20 2010-11-21 Bayer Schering Pharma Oy Vaginaalinen antojärjestelmä
AU2011238710B2 (en) * 2010-03-28 2015-08-20 Evestra, Inc. Intravaginal drug delivery device
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
KR20130045332A (ko) * 2010-06-22 2013-05-03 지아시앙 차오 항콜린제를 포함하는 질내 기구 및 그 제조방법
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
KR101993786B1 (ko) * 2010-11-12 2019-06-28 더 유니버시티 오브 유타 리서치 파운데이션 윤활제의 제어된 전달을 위한 질내 장치
CN103249421B (zh) * 2010-11-29 2015-05-20 株式会社明治 子宫内膜异位症的预防和/或改善剂以及含有其的饮食品组合物
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
KR101263916B1 (ko) 2011-01-11 2013-05-13 이장희 성 호르몬 방출 장치 및 이를 이용한 동물 피임 및 발정 유도 방법
EP2717813B1 (en) * 2011-06-06 2020-05-20 Auritec Pharmaceuticals Drug delivery device employing wicking release window
JP6010120B2 (ja) * 2011-07-15 2016-10-19 ウニベルシテイト ヘント 膣内送達システム
BR112014001450A2 (pt) * 2011-07-20 2017-07-18 F Kiser Patrick dispositivos intravaginais para distribuição de droga
EP2749286B1 (en) 2011-08-26 2017-03-01 Universidad De Santiago De Chile Use of non-steroidal anti-inflammatory drugs meloxicam and piroxicam, administered intravaginally, for interruption of a woman's ovulation process
CN103007427B (zh) * 2011-09-21 2016-01-20 上海市计划生育科学研究所 缓控释宫内释药器及其制备方法
TWI615155B (zh) * 2011-11-01 2018-02-21 拜耳股份有限公司 滲透活性的陰道遞送系統
AR089765A1 (es) 2012-01-23 2014-09-17 Bayer Oy Un sistema para el suministro de un farmaco
CA2873967A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
CN104487054A (zh) 2012-06-13 2015-04-01 伊沃菲姆股份有限公司 用于增强避孕杀微生物剂有效性的组合物和方法
PT2893804T (pt) 2012-09-03 2018-06-26 Ecosea Farming S A Sistema de imersão de um reservatório-jaula destinado à cultura e/ou contenção de espécies hidrobiológicas
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014066480A1 (en) * 2012-10-23 2014-05-01 Estech Usa, Llc Treating conditions caused by abnormal growth of pathogens in body cavities
MX374990B (es) 2013-02-04 2025-03-06 Pilot Polymer Tech Inc Métodos para la elaboración de macromoléculas en forma de estrella tolerantes a las sales que comprende una pluralidad de brazos poliméricos.
SE539540C2 (sv) * 2013-09-12 2017-10-10 Qpharma Ab Ett läkemedelsavgivningssystem för en eller flera aktiva beståndsdelar
BR112016010103A8 (pt) * 2013-11-05 2018-01-30 Taris Biomedical Llc métodos, kits e dispositivos de suprimento de fármaco osmótico.
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
MX2016008023A (es) 2013-12-19 2017-01-13 Evofem Inc Composiciones y metodos para inhibir la inflamacion y las enfermedades utilizando un compuesto antimicrobiano con base en acido alginico.
JP6667450B2 (ja) * 2014-04-01 2020-03-18 ポリ−メッド インコーポレイテッド 避妊具及び関連した器具
MX385886B (es) 2014-07-03 2025-03-18 Pilot Polymer Tech Inc Macromoleculas estrellas compatibles con tensoactivos.
CN105250280B (zh) 2014-07-14 2020-03-10 诺维科国际控股股份有限公司 包含辛苯聚醇和喹诺里西啶生物碱化合物或其来源的杀微生物组合物
CN104117135A (zh) * 2014-08-11 2014-10-29 崔仁海 阴道内植入式治疗装置
CN104558491A (zh) * 2014-12-25 2015-04-29 中南大学 能促进组织内膜生长的聚氨酯材料的制备方法
ES3009909T3 (en) * 2015-05-13 2025-03-31 Bayer Oy Long acting drug delivery device in form of an implant or iud comprising levonorgestrel and ethinylestradiol
EP3344749A1 (en) * 2015-08-31 2018-07-11 Chr. Hansen A/S Lactobacillus fermentum bacteria with antifungal activity
KR20180093255A (ko) * 2015-12-21 2018-08-21 바이엘 오와이 질용 고리의 제조 방법
EP3393452B1 (en) * 2015-12-21 2021-08-04 Bayer Oy Method for manufacturing a drug delivery device
WO2017117627A1 (en) * 2016-01-04 2017-07-13 Jurox Pty Ltd Drug release device and use
KR101720145B1 (ko) * 2016-07-08 2017-04-07 (주)정가진면역연구소 여성 질염 예방 및 개선 기능성 조성물
US11419835B2 (en) 2016-10-04 2022-08-23 Evofem, Inc. Method of treatment and prevention of bacterial vaginosis
BR112020005928A2 (pt) * 2017-09-27 2020-10-06 Bayer Oy método para modificar a liberação de um agente terapeuticamente ativo de uma matriz elastomérica.
WO2019210066A1 (en) * 2018-04-27 2019-10-31 Evestra, Inc. Estrogen prodrugs and methods of administering estrogen prodrugs
AU2019275406B2 (en) 2018-05-24 2024-11-14 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
WO2019226519A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
WO2020007780A1 (en) * 2018-07-02 2020-01-09 Artpred B.V. Method and kit for altering the outcome of an assisted reproductive technology procedure
KR102078462B1 (ko) * 2018-07-24 2020-02-17 주식회사 디네이쳐 질환경 개선 조성물 및 이를 포함하는 개선제
DE102019115343A1 (de) * 2019-06-06 2020-12-10 EVESTRA GmbH Vaginalring für die hormonelle Kontrazeption
CN110585246B (zh) * 2019-09-22 2020-06-02 深圳市多微生保健食品有限公司 一种阴道抑菌制剂及其制备方法
AU2020384227B2 (en) * 2019-11-12 2026-02-19 Poly-Med, Inc. Contraceptive medical devices
KR20210097421A (ko) * 2020-01-30 2021-08-09 주식회사 디네이쳐 펄스형 질내 약산성 환경 유지 조성물
IT202000029267A1 (it) * 2020-12-01 2022-06-01 Francesca FRIZZI Dispositivo vaginale
WO2022231930A1 (en) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
EP4215181A1 (en) * 2022-01-21 2023-07-26 Sever Pharma Solutions An intravaginal ring
WO2023200974A1 (en) * 2022-04-14 2023-10-19 Yale University Nanoparticles and nanoparticle-releasing vaginal rings
WO2024030116A1 (en) * 2022-08-01 2024-02-08 Lupin Inc. Drug delivery system for ultra-low dose estrogen combinations and methods and uses thereof
WO2025233917A1 (en) * 2024-05-10 2025-11-13 Millicent Pharma Limited A vaginal system containing a core, and methods of manufacture and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48277A (en) * 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US4237885A (en) * 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
DE3040978A1 (de) * 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
EP0180264A1 (en) * 1984-10-12 1986-05-07 Akzo N.V. Release system for two or more active substances
FR2618329B1 (fr) * 1987-07-22 1997-03-28 Dow Corning Sa Procede de fabrication d'un anneau capable d'assurer la liberation d'un agent therapeutique, et anneau fabrique par ce procede
FI95768C (fi) * 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US6544546B1 (en) * 1995-07-04 2003-04-08 Akzo Nobel, N.V. Ring-shaped devices
US5972372A (en) * 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
US6063395A (en) * 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
EP1406634A1 (en) * 2001-07-13 2004-04-14 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
CN1289064C (zh) * 2001-08-31 2006-12-13 先灵有限责任公司 药物输送体系
CA2461708C (en) * 2001-09-28 2012-08-07 Nutraceutix, Inc. Delivery system for biological component
US20040247574A1 (en) * 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
AU2004274000B2 (en) * 2003-09-19 2009-07-30 Drugtech Corporation Pharmaceutical delivery system
US8481079B2 (en) * 2004-03-24 2013-07-09 Merck Sharp & Dohme B.V. Drug delivery system based on polyethylene vinylacetate copolymers
US20060183724A1 (en) * 2005-02-03 2006-08-17 Diliberti Charles E Compositions of unconjugated estrogens and methods for their use
CA2614187A1 (en) * 2005-07-15 2007-01-25 Bayer Schering Pharma Aktiengesellschaft Drospirenone containing transdermal drug delivery devices and methods of delivery thereof

Also Published As

Publication number Publication date
CA2705734A1 (en) 2009-05-28
JP2011504484A (ja) 2011-02-10
ZA201002122B (en) 2011-06-29
SG186002A1 (en) 2012-12-28
CO6290642A2 (es) 2011-06-20
NZ584216A (en) 2012-03-30
AR069379A1 (es) 2010-01-20
CN101873850A (zh) 2010-10-27
EP2227220A1 (en) 2010-09-15
US20090142313A1 (en) 2009-06-04
SV2010003513A (es) 2010-08-09
DOP2010000154A (es) 2010-07-31
PE20091025A1 (es) 2009-08-17
UY31475A1 (es) 2009-07-17
PA8805001A1 (es) 2009-06-23
KR20100090708A (ko) 2010-08-16
BRPI0815936A2 (pt) 2019-08-27
CR11493A (es) 2010-08-23
IL205588A0 (en) 2010-11-30
MX2010003656A (es) 2010-04-21
EA018112B1 (ru) 2013-05-30
WO2009066006A1 (en) 2009-05-28
CL2008003421A1 (es) 2009-08-07
TW200927141A (en) 2009-07-01
US20100285097A1 (en) 2010-11-11
EA201070639A1 (ru) 2010-10-29
AU2008327813A1 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
CO6290642A2 (es) Sistema, dispositivo y método mejorados para administrar vaginalmente sustancias terapeuticamente activas o sus profarmacos
WO2010011609A3 (en) Controlled release antimicrobial compositions and methods for the treatment of otic disorders
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
CL2008002810A1 (es) Sistema de entrega de drogas de tres capas, cuyas capas nucleos e intermedia comprende un polimero termoplastico y cristales de una droga y una capa piel de polimero termoplastico no medicada sobre la capa intermedia; metodo para prepararla; uso como anticonceptivo, en terapia de reemplazo hormonal y para tratar o prevenir enfermedades de transmision sexual.
WO2012027065A3 (en) Combination therapy for treatment of disease
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
GT200900328A (es) Derivados de bencimidazol
CL2012002126A1 (es) Composicion farmaceutica topica que comprende 1`-{[5-(trifluorometil)furan-2-il]metil}espiro[furo[2,3-f][1,3]benzodioxol-7,3`-indol]-2`(1`h)-ona; y uso para tratar, una enfermedad o condicion tal como dolor neuropatico, dolor quirurgico, dolor por trauma, dolor de cabeza cronico, entre otras.
MX2019000547A (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
UY32327A (es) Antagonistas de receptores de ácido lisofosfatídico
CL2008001114A1 (es) Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras.
CL2007002356A1 (es) Sistema de liberacion farmaceutica que comprende flibanserina y por lo menos un excipiente farmaceuticamentre aceptable; y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, del sueno y sexuales, entre otros.
IN2012DN02735A (es)
IN2012DN00754A (es)
DK201470535A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
CL2008003549A1 (es) Compuestos derivados de glucocorticoides; procedimientos de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades a la piel como eczema, afecciones a la nariz, garganta y pulmones como rinitis o asma, enfermedades inflamatorias del intestino, oculares y autoinmunes.
PA8849701A1 (es) Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de anglotensina ii y/o un diuretico
PE20160680A1 (es) Sistema de administracion farmacologica
MX2011009847A (es) Agentes antihelminticos y su uso.
WO2009048594A3 (en) Multicomponent bioactive intravaginal ring
CL2008002984A1 (es) Composicion farmaceutica que comprende micofenolato sodico y su uso para el tratamiento y/o prevencion en enfermedades autoinmunes tales como el rechazo de aloinjertos o xenoinjertos de organos, celulas o tejidos y como antiinflamatorio.
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
MY172530A (en) Method for treating gynecological diseases
AR076588A1 (es) Sistema de liberacion vaginal